RecruitingNot ApplicableNCT06523868

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study


Sponsor

Dana-Farber Cancer Institute

Enrollment

1,500 participants

Start Date

Mar 31, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this research study is to evaluate the possible benefits of an investigational, but commercially available Galleri multi-cancer early detection (MCED) blood test which is designed to detect many types of cancer early in veterans who have served in the military in active duty. The name of the screening blood test being studied is: -GRAIL Galleri MCED test


Eligibility

Min Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying GRAIL Galleri for people with cancer diagnosis. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERGRAIL Galleri

A multi-cancer early detection (MCED) blood test.


Locations(1)

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06523868


Related Trials